Home/Pipeline/Unnamed Breast Cancer Program

Unnamed Breast Cancer Program

Breast Cancer

Pilot/Phase 2Active

Key Facts

Indication

Breast Cancer

Phase

Pilot/Phase 2

Status

Active

Company

Click Therapeutics

About Click Therapeutics

Click Therapeutics is redefining modern medicine by developing patient-centric digital treatments delivered via smartphone and prescribed by physicians. The company leverages a multimodal, platform-based approach that combines scientifically proven therapies with proprietary neuromodulatory mechanisms to drive clinically meaningful outcomes. With an FDA-cleared product for depression and multiple Phase 3 programs in neurology and psychiatry, Click is positioned at the forefront of the rapidly evolving digital therapeutics market. Their innovative Software-Enhanced Drugs™ platform represents a novel approach to enhancing traditional pharmacotherapy through digital interventions.

View full company profile

Therapeutic Areas

Psychiatry Neurology Oncology

Other Breast Cancer Drugs

Drug	Company	Phase	Status
Antifibrotic Therapy Program	MeCo Diagnostics	Pre-clinical	Active
inPROBE for HER2	SDS Optic	Clinical Investigation	Completed (March 2023)
ACT‑BC1	Anthrocell	Preclinical	Active
APA-1000 Breast Thermotherapy System	Medifocus	Phase III	Pivotal Trial Approved (IDE/ITA)
Early‑Detection Breast Cancer Screening	Karkinos Healthcare	Market	Active
Lerociclib (Lerocliclib)	Chemogenics BioPharma	Phase 3	Completed Phase 3, awaiting FDA approval
AT-017	Asieris Pharmaceuticals	Not Specified	Active
CDK2 inhibitor	Acellera	Pre-clinical	Hit Identification
NP-G2-044	Novita Pharmaceuticals	Phase 2a	Active (subset)
Maveropepimut-S (MVP-S)	BioVaxys	Clinical Evaluation	Active
Cannabics® BRST-33	CNBX Pharmaceuticals	Discovery	In vitro POC
Undisclosed	Biossil	Phase 2/3	Active